text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 162401-32-3 | Product Number: R0193

Roflumilast


Purity: >98.0%(HPLC)
Synonyms:
  • 3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
Product Documents:
250MG
£52.00
1   20  
1G
£158.00
18   27  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number R0193
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__7H__1__4Cl__2F__2N__2O__3 = 403.21 
Physical State (20 deg.C) Solid
Storage Temperature Frozen (-20°C)
Condition to Avoid Heat Sensitive
CAS RN 162401-32-3
Reaxys Registry Number 9802592
PubChem Substance ID 354334855
Merck Index (14) 8249
MDL Number

MFCD00938270

Specifications
Appearance White to Orange to Green powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(with Total Nitrogen) min. 97.0 %
Melting point 157.0 to 161.0 °C
Properties (reference)
Melting Point 159 °C
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
Precautionary Statements P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
Related Laws:
RTECS# CV3325600
Transport Information:
HS Number 2933399990
Application
Roflumilast: A Selective Phosphodiesterase 4 (PDE4) Inhibitor.

R0193

Roflumilast is a selective phosphodiesterase 4 (PDE4) inhibitor. The active metabolite, Roflumilast N-oxide [R0217], also acts as a selective PDE4 inhibitor. PDE4 is a key enzyme in the degradation of cyclic adenosine monophosphate (cyclic AMP) [A2381] and is centrally involved in the cytokine production of inflammatory cells. The inhibition of PDE4 activity leads to accumulation of intracellular cyclic AMP. Roflumilast is used for the treatment of chronic obstructive pulmonary disease (COPD). While the precise mechanism of the therapeutic action in COPD is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells. For your reference, [C3395] and [D4505] are synthetic intermediates of roflumilast. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.